Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human GEN1078 in Malignant Solid Tumors
2024-515752-21-00Phase 2Completed
- Sponsor
- Genmab
- Start
- Dec 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of GEN1078 in Non-hematologic malignancy (2 arms), sponsored by Genmab. Primary endpoints: Dose Escalation: Number of Participants with Dose-limiting Toxicities (DLTs), Dose Escalation: Number of Participants with Adverse Events (AEs) and 1 more. Started Dec 2024; status: completed.
02
Drugs
GEN1078
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2024-515752-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515752-21-00.